Research Analysts Set Expectations for PLX FY2025 Earnings

Key Points

• HC Wainwright has revised its FY2025 earnings per share (EPS) estimate for Protalix BioTherapeutics from $0.14 to $0.05, reflecting a significant pessimistic outlook.
• Wall Street Zen downgraded Protalix BioTherapeutics from a "strong-buy" to a "buy" rating, although the stock still holds a consensus "Buy" rating with a target price of $15.00.
• Insider transactions showed Director Aharon Schwartz purchased 129,000 shares at $1.60 per share, increasing his ownership by 74.14% amid overall stock ownership of 6.50% by insiders.

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Equities research analysts at HC Wainwright cut their FY2025 earnings per share estimates for shares of Protalix BioTherapeutics in a research note issued on Monday, August 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.05 for the year, down from their prior forecast of $0.14. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share.

Separately, Wall Street Zen lowered Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 12th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Protalix BioTherapeutics currently has a consensus rating of "Buy" and an average price target of $15.00.

Protalix BioTherapeutics Stock Down 2.1%

Shares of NYSE:PLX traded down $0.0350 during trading on Wednesday, reaching $1.6250. 289,531 shares of the company's stock traded hands, compared to its average volume of 832,071. Protalix BioTherapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $3.10. The firm has a market cap of $129.56 million, a PE ratio of -12.50 and a beta of -0.21. The company has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $2.00.

Insider Activity

In related news, Director Aharon Schwartz acquired 129,000 shares of Protalix BioTherapeutics stock in a transaction dated Tuesday, June 10th. The shares were acquired at an average cost of $1.60 per share, for a total transaction of $206,400.00. Following the completion of the purchase, the director owned 303,000 shares in the company, valued at approximately $484,800. The trade was a 74.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.50% of the company's stock.

Institutional Trading of Protalix BioTherapeutics

Several hedge funds have recently modified their holdings of PLX. Cubist Systematic Strategies LLC increased its stake in shares of Protalix BioTherapeutics by 24.1% during the fourth quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company's stock worth $55,000 after buying an additional 5,686 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Protalix BioTherapeutics by 13.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 53,507 shares of the company's stock worth $101,000 after buying an additional 6,434 shares during the period. Orin Green Financial LLC increased its stake in shares of Protalix BioTherapeutics by 22.4% during the second quarter. Orin Green Financial LLC now owns 61,200 shares of the company's stock worth $91,000 after buying an additional 11,200 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Protalix BioTherapeutics by 2.8% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 496,216 shares of the company's stock worth $734,000 after buying an additional 13,341 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Protalix BioTherapeutics by 3.8% during the fourth quarter. Millennium Management LLC now owns 387,921 shares of the company's stock worth $729,000 after buying an additional 14,164 shares during the period. 16.53% of the stock is currently owned by institutional investors and hedge funds.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.